ÂÜÀòÂÒÂ×

Troy A. Ignelzi has served as Karuna’s Chief Financial Officer since March 2019. He has spent 25 years supporting companies in finance, business development and operations. He joins Karuna from scPharmaceuticals, where in his role as Chief Financial Officer, he helped oversee development from a privately-held clinical-stage company to a publicly-traded biopharma preparing for commercial launch. Prior to scPharmaceuticals, Mr. Ignelzi was a senior executive at Juventas Therapeutics, Esperion Therapeutics, and Insys Therapeutics, helping raise public/private capital, expand development pipelines through licensing/acquisition and advancing critical therapies, several of which are currently approved by the FDA. He also brings relevant commercial experience, having launched and promoted CNS therapies while at Eli Lilly.

Mr. Ignelzi holds a bachelor’s degree in Accounting from Ferris State University.